Looking back on 2022, investment and financing in the field of medicine and biology can be said to be very active
.
At the beginning of 2023, the pharmaceutical and biological track has been continuously coming with good news
in terms of investment and financing.
Recently, Shenzhen Junsheng Tai Biotechnology Co.
, Ltd.
(hereinafter referred to as Shenzhen Jun Shengtai) announced the completion of a $107 million C/C+ round of financing
.
The round of financing was led by China Development Bank Capital and Guangdong Traditional Chinese Medicine Health Fund managed by Guangdong State-owned Assets, with the participation of Yuexiu Industrial Fund, Yuefeng Shengtai's fund of 10 billion capital and related enterprises
.
According to the data, Junsheng Tai is a global integrated clinical-stage biotechnology company, focusing on metabolic diseases, digestive diseases and other fields
.
Since its establishment, the company has built a rich multi-target original innovative drug pipeline based on traditional natural drugs with clear pharmacological activity, integrating modern drug design and development concepts, such as HTD1801, HTD1804, HTD1805, HTD4010, HTD2802 and a series of projects, which fully demonstrate the company's strong independent research and development capabilities
.
Among them, HTD1801 is the core product of Jun Shengtai, which is a new molecular entity
synthesized by berberine (also known as berberine, the main active ingredient in the traditional Chinese medicine Coptis and Huangbai) and ursodeoxycholic acid.
At present, it has been awarded 2 "Fast Track Qualification Certification" and 1 "Orphan Drug Qualification Certification" by the US FDA, and has received major scientific and technological special support
from the National 13th Five-Year Plan "Major New Drug Creation Project".
On January 5, Shanghai Inokic Biotechnology Co.
, Ltd
.
(hereinafter referred to as Inochco) announced the completion of an angel round of financing of RMB 50 million, invested by Jingsheng Capital and Waige Capital.
This round of financing will be used to accelerate the construction and operation of production facilities, the R&D of pipelines, and the expansion
of talent teams.
Enokico is a synthetic biology company dedicated to the development and production of green biological products, covering natural flavors, nutrition and health, biomedicine and other fields
.
The company's different links from R&D to production to sales have all been opened
.
On the same day, Zhen Biotechnology (Suzhou) Co.
, Ltd.
(hereinafter referred to as Bozhen Biotechnology) also announced the completion of a series A financing
of nearly 100 million yuan.
This round of financing was led by SDIC Investment Promotion, and the original shareholder Yuanyi Capital followed the investment
in excess of the proportion.
With this round of financing, Bozhen Biotech will further improve the organoid CDMO and CRO process technology system, accelerate the construction and operation of commercial production bases, and explore overseas markets
.
It is understood that Bozhen Biotech is deeply engaged in the underlying technological innovation of the organoid industry, has professional organoid model construction capabilities, and is committed to providing standardized and modular organoid products and technical support
for biomedical scientific research, drug research and development and clinical precision medicine.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
